Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 4Sarcoma 3Plasma cell 3Lymphoid 3Head & Neck 2CNS 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1NET 1Gynecologic 1Endocrine 1Dermatologic 1Breast 1

Conditions

Metastatic Digestive System Neuroendocrine Tumor G1 1

Interventions

lutetium Lu 177 dotatate 6Specimen Handling 4Magnetic Resonance Spectroscopy 4cabozantinib 3pembrolizumab 2olaparib 2fludarabine 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 2tivozanib 1repotrectinib 1pazopanib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Watchful Waiting 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Sunitinib 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sunitinib × NET × 30 days × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡